
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
With the election of Senator Bill Frist, MD (R-Tenn.), as leader of the Senate, physicians can expect health-related issues to receive intense and sympathetic attention in Congress.






